IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Re: Docket No. 202**

DECLARATION IN SUPPORT OF EMPLOYMENT OF HOGAN LOVELLS CADWALADER (PARIS) LLP
AS A PROFESSIONAL UTILIZED IN ORDINARY COURSE OF BUSINESS

I, Xavier Doumen, pursuant to 28 U.S.C. § 1746, hereby declare that the following is true to the best of my knowledge, information, and belief.

1. I am Xavier Doumen, Partner of Hogan Lovells Cadwalader Paris LLP located at 17 avenue Matignon - 75008 Paris, France (the "**Firm**"), which has been employed by Sangamo Therapeutics, Inc. (the "**Debtor**") in the above-captioned Chapter 11 case (the "**Chapter 11 Case**"), in the ordinary course of the Debtor's business. The Debtor wishes to retain the Firm to continue providing ordinary course services during the Chapter 11 Case, and the Firm has consented to provide such services. This Declaration is submitted in compliance with the *Order (I) Authorizing Employment and Compensation of Professionals Utilized in the Ordinary Course of Business and (II) Granting Related Relief* (the "**Ordinary Course Professionals Order**"). I have reviewed the Ordinary Course Professionals Order, and I understand the limitations on compensation and reimbursement under such order.

2. Historically, Hogan Lovells Cadwalader Paris LLP advised the Debtor and its French subsidiary, Sangamo Therapeutics France S.A.S, on a range of French law matters,

[1] The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor's mailing address is 7000 Marina Blvd, Brisbane, CA 94005.

2610989261028000000000001

including tax, corporate and regulatory matters. Following the commencement of the Chapter 11 proceedings, and based on this relationship and familiarity with the Debtor and its French subsidiary, the Debtor requested that Hogan Lovells Cadwalader Paris LLP provide French law advice to the Debtor in connection with matters relating to the French subsidiary.

3. The Firm may have performed services in the past, may currently perform services, and may perform services in the future in matters unrelated to the Debtor or to the Chapter 11 Case for persons that are parties in interest in the Chapter 11 Case. The Firm does not perform services for any such person in connection with the Debtor or the Chapter 11 Case, or have any relationship with any such person, their attorneys, or their accountants that would be adverse to the Debtor or its estate.

4. Neither I nor any principal, partner, director, or officer of, or professional employed by the Firm has agreed to share or will share any portion of the compensation to be received from the Debtor with any other person other than the principal and regular employees of the Firm.

5. Neither I nor any principal, partner, director, or officer of, or professional employed by, the Firm, insofar as I have been able to ascertain, holds or represents any interest adverse to the Debtor or its estate with respect to the matter(s) upon which the Firm is to be employed.

6. The Firm is not an equity holder or insider of the Debtor and is not and was not, within 2 years before the Petition Date (as defined below), a director, officer, or employee of the Debtor.

7. The Firm intends to bill the Debtor for professional services rendered in connection with the Chapter 11 Case, in accordance with the Ordinary Course Professionals Order, with such bill to include compensation for services based on the hourly rates set forth below, plus reimbursement of actual and necessary expenses and other charges incurred by the Firm. The

principal Partner, associate and Paralegal designated to represent the Debtor and their current standard rates are:

Timekeeper name	**Rate in USD**
Partner	1,585.00 – 1,665.00
Senior Associate	1,500.00 – 1,185.00
Associate	1,185.00 – 1,105.00
Paralegal	435.00

8. The rates set forth above are subject to periodic adjustments to reflect economic and other conditions. Such rates are the Firm's standard rates for work of this nature. The rates are set at a level designed to fairly compensate the Firm for the work of its attorneys and paralegals and to cover fixed and routine overhead expenses.

9. It is the Firm's policy to charge its clients in all areas of practice for all other expenses incurred in connection with a client's case. The expenses charged to clients include, the fees and expenses of third-party professionals whose involvement may be required in connection with certain proceedings in France involving Sangamo Therapeutics France S.A.S., as well as, in general, all identifiable expenses that would not have been incurred except for representation of a particular client. The Firm will charge the Debtor for these expenses in a manner and at rates consistent with charges made generally to the Firm's other clients and consistent with the expenses allowed under the Local Rules.

10. The Firm does in the ordinary course of business, maintain time records in tenth-of-an-hour increments.

11. No representations or promises have been received by the Firm, nor by any principal, partner, director, officer, or professional thereof, as to compensation in connection with the Chapter 11 Case other than in accordance with the provisions of the Bankruptcy Code. The Firm has no agreement with any other entity to share with such entity any compensation received by the Firm in connection with the Chapter 11 Case.

12. As of June 23, 2026 (the "**Petition Date**"), the Debtor owed the Firm $0[2] for fees and expenses incurred for pre-petition services.

13. As of the Petition Date, the Firm held a pre-petition retainer of $0.

14. As of the Petition Date, the Firm was not party to an agreement for indemnification with the Debtor.

15. The Firm obtained a list of potentially interested parties from counsel to the Debtor, which includes the Debtor, its significant creditors and potential parties in interest, and certain professionals employed in this Chapter 11 Case (the "**Potential Parties in Interest**"), which is attached hereto as **Exhibit A**, and undertook a search for any connections between the Firm and Potential Parties in Interest. Pursuant to Bankruptcy Rule 2014, the Firm hereby confirms that, to the best of its knowledge and belief, and except as may be set forth on an exhibit attached hereto, the Firm does not have any connection with the Potential Parties in Interest, except that the Firm previously represented the Debtor's French subsidiary, Sangamo Therapeutics France S.A.S., in connection with general corporate matters, and such matter concluded in 2025. The Firm understands that the French subsidiary may in the future retain the Firm in connection with the subsidiary's potential internal reorganization under French law.

[2] On September 21, 2026, the Firm filed Proofs of Claim Nos. 393 and 405. Following the submission of such proofs of claim the Firm determined that they were filed in error. Accordingly, the Firm intends to withdraw Proofs of Claim Nos. 393 and 405.

16. The Firm is conducting further inquiries regarding its retention by any creditors of the Debtor, and upon conclusion of such inquiries, or at any time during the period of its employment, if the Firm should discover any facts bearing on the matters described herein, the Firm will supplement the information contained in this Declaration.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Dated: 28 October 2026



Xavier Doumen
Partner
Hogan Lovells Cadwalader (Paris) LLP
17, avenue Matignon -75008 Paris
Xavier.doumen@hlc.com

Exhibit A

Potential Parties in Interest

Banks
HSBC UK Bank, PLC
J.P. Morgan
Silicon Valley Bank
US Bank
Wells Fargo Bank

Bankruptcy Court Staff
Barksdale, Nickita
Batts, Cacia
Bello, Rachel
Brady, Claire
Capp, Laurie
Gadson, Danielle
Grant, Stephen L.
Haney, Laura
Hrycak, Amanda
Johnson, Lora
Lopez, Marquietta
Lugano, Al
Subda, Paula
Walker, Jill
Yeager, Demitra

Bankruptcy Judges
Goldblatt, Craig T.
Horan, Thomas M.
Owens, Karen B.
Shannon, Brendan L.
Silverstein, Laurie Selber
Stickles, Kate J.
Walrath, Mary F.

U.S. Trustee Staff
Attix, Lauren
Casey, Linda
Dice, Holly
Dortch, Shakima L.
Girello, Michael
Green, Christine
Hackman, Benjamin
Jones, Nyanquoi
Konde, Hawa
Leamy, Jane
Lipshie, Jonathan
McCollum, Hannah M.
McMahon, Joseph
Nyaku, Jonathan
O'Malley, James R.
Serrano, Edith A.
Thomas, Elizabeth
Vara, Andrew
Wynn, Dion

Contract Counterparties
ACAC Enterprises, LLC
ACT for Health, Inc. dba Professional Case Management
Actalent Scientific, LLC
Advanced Cell Diagnostics, Inc.
Aerotek Scientific, LLC
Agriculture Victoria Services Pty. Ltd.
Agrisoma Biosciences, Inc.
American Type Culture Collection
ARC Regulatory Limited
Armature Systems, Inc.
Astellas Gene Therapies, Inc.
AstraZeneca PLC
Benchling, Inc.
BioAgilytix Labs, LLC
Biogen Idec MA Inc.
Bio-Rad AbD Serotec GmbH
BioReliance Corporation
Bioverativ Therapeutics Inc.
C R Williams Consulting LLC
California Institute of Technology
Catalent Gosselies PS S.A.
Catalent Maryland, Inc.
CBRE, Inc.
Charles River Laboratories, Inc.
CHDI Management/CHDI Foundation
Children's Medical Center Corporation
Chroma Medicine, Inc.
Connor Group Global Services, LLC
Corbus, LLC
Corteva Agriscience LLC
CTI Clinical Consulting Services, Inc.
Cyprotex Discovery Limited
Dow Agrosciences LLC
East West Bank
Eli Lilly and Company
Elim Biopharmaceuticals, Inc.

Elpis Biomed Limited
Ernst & Young LLP
Evotec International GmbH
F. Hoffmann-La Roche Ltd
Fisher BioServices, Inc.
Foley & Lardner LLP
Framework Solutions LLC
FUJIFILM Cellular Dynamics, Inc.
GemPharmatech Corporation
Genentech, Inc.
GeneScience Pharmaceutical Co., Ltd
GraphPad Software, LLC
Groupware Technology, Inc.
Hoffmann-La Roche Inc.
ICON Clinical Research Limited
Inserm Transfert SA
JAGGAER, LLC
Kite Pharma, Inc.
Life Sciences Advisors, LLC
Life Technologies Corporation
Marina Boulevard Property, LLC
Marina Landing Property, LLC
Memorial Sloan-Kettering Cancer Center, Sloan Kettering Institute for Cancer Research and Memorial Hospital for Cancer and Allied Diseases
Merope Acquisition Sub, LLC
Miltenyi Biotec B.V. & Co. KG
MP Biomedicals, LLC
National Institutes of Health
Nisos Group
Novartis Institutes for BioMedical Research
Open Monoclonal Technology, Inc.
Oracle American, Inc.
Pacific BioLabs, Inc.
Perspective Pharmacovigilance, Inc.
Pfizer, Inc.
Prevail Therapeutics, Inc.
Promega Corporation
PSI CRO AG
Public Health Service
Q-Square Business Intelligence Corporation
Roche Diagnostics
Rothwell, Figg, Ernst & Manbeck, P.C.
Saatzucht Josef Breun GmbH & Co. KG
SAGE Acquisition Co.
Samsung Biologics
Sartorius Stedim North America Inc.
Sentry BioPharma Services, Inc.
SHI International Corp
Shire AG
Shire Human Genetic Therapies, Inc.
Shire International GmbH
Sigma-Aldrich Co., LLC
Solvo Biotechnology
Standard Biotools
Syneos Health, LLC
Syneos Health UK Limited
Syner-G BioPharma Group LLC
Takeda Pharmaceuticals Inc Co.
T&C Janitorial and Building Maintenance, Inc.
The Ascent Services Group, Inc.
The Board of Trustees of the Leland Stanford Junior University
Thermo Fisher Scientific, Inc.
Twist Bioscience Corporation
UBS Securities LLC
University of Utah Research Foundation
Unum Life Insurance Company of America
UW Center for Commercialization
Veeva Systems, Inc.
Vrije Universiteit Brussel
Wynden Start LLC d/b/a GQR Global Markets
Yurogen Biosystems LLC

Debtors & Non-Debtor Affiliates (not otherwise mentioned)

Ceregene, Inc.
Sangamo Therapeutics France S.A.S
Sangamo Therapeutics, Inc.
Sangamo Therapeutics UK Ltd.

Debtors' Professionals & Advisors

Cooley, LLP
Evercore Group Inc.
Kohlberg Kravis Roberts & Co. (KKR)
Kurtzman Carson Consultants, LLC (KCC) dba Verita Global
MERU, LLC
Raymond James Financial, Inc.

Richards, Layton & Finger (RLF)

Committee of Unsecured Creditors Members and Professionals
Beckman Coulter, Inc.
Boston Children's Hospital
Brammer Bio MA, LLC
Charles River Corp.
IQVIA Inc.
IQVIA RDS Inc.
M3 Advisory Partners, LP
McDermott Will & Schulte LLP

Committee of Equity Holders Members and Professionals
Charlestown Jupiter Fund, LLC
Foley, Frank J.
Grossman, Kenneth
Jalagam, Venkata
Nagin, Adam
Morris James LLP
Orrick, Herrington & Sutcliffe LLP
Dundon Advisers LLC

Directors & Officers (Current/Former)
Beers, Courtney
Carey, Robert F.
Ceniceros, Michael
Davis, Gregory
Dubois-Stringfellow, Nathalie
Duraibabu, Prathyusha
Fontenot, Jason
Glasser, Julie
Hillan, Kenneth J.
Horn, Margaret A.
Jain, Nikunj
Macrae, Alexander D.
Markels, John H.
McClung, Mark
Meyers, James R.
Parker, H. Stewart
Pooler, Amy
Smith, Karen L.
Willoughby, Scott B.

DIP Lender and Professionals
Future Solution Investments LLC
KTBS Law
Young Conaway Stargatt & Taylor
PwC US Business Advisory LLP

Successful and Backup Bidders
PTC Therapeutics, Inc.
Surplus Solutions, LLC
TerSera Therapeutics, Inc.
Heritage Global Partners, Inc.

Insurance Providers
Accredited Insurance Program Management
Aetna
Allied World Assurance Company (U.S.), Inc.
American International Group, Inc. (AIG)
Anthem Blue Cross
Arthur J. Gallagher Risk Management Services, LLC
AXA XL Insurance
Beazley Excess & Surplus Insurance
Berkley Life Sciences, LLC
Berkley National Insurance Company
Berkshire Hathaway Specialty Insurance
Chubb National Insurance Company
Cigna Health and Life Insurance Company
Delta Dental of California
Endurance Risk Solutions Assurance Co.
Falvey Cargo Underwriting
Falvey Insurance Group
Federal Insurance Company
First Insurance (not in Oracle)
Fubon Insurance Co., Ltd.
Great American Insurance Group
Guardian
Hudson Insurance Company
Kaiser Foundation Health Plan
MCI Life Sciences & Healthcare Consortium 4985 at Lloyd's
National Union Fire Insurance Company of Pittsburgh, PA
Old Republic Insurance Company
Old Republic Professional Liability, Inc.
Provident Life And Accident Insurance Company

Sentry Specialty
SI Insurance (Europe) S.A
Sompo International
The Hartford Insurance
Underwriters at Lloyd's London (including Lloyd's of London)
United HealthCare Insurance Company
Vision Service Plan (VSP)
XL Specialty Insurance Company
Zurich American Insurance Company

Landlords
Point Richmond R&D Associates
Point Richmond R&D Associates II, LLC
PPF OFF 7000 Marina Blvd LP

Litigation Parties
None

Secured Creditors
None

Material (5% or Greater) Shareholders
Armistice Capital LLC
Yorkville Advisors Global LP

Top 20 Creditors
Beckman Coulter, Inc.
Brammer Bio, LLC
Catalent Pharma Solutions
Charles River Laboratories Montreal ULC
Children's Hospital Corp.
Computer Packages Inc.
CTI Clinical Trial Svs, Inc
Envol Biomedical, LLC
EPL Archives, Inc
Innova Solutions, Inc
IQVIA RDS Inc.
Laboratory Corporation of America
Meet Recruitment Inc.
Point Richmond R&D Ass. II LLC
PPD Development, L.P.
PPF OFF 7000 Marina Blvd LP
Snell & Wilmer L.L.P.
Sterne, Kessler, Goldstein & Fox P.L.L.C
TraceLink Inc
VWR International, Inc.

Taxing Authorities
California Department of Tax and Fee Administration
California Franchise Tax Board
City of Richmond Finance Department, Business License Division
Contra Costa County Tax Collector
Internal Revenue Service
Internal Revenue Service (PA)
Massachusetts Department of Revenue
New York State Corporation Tax Department of Taxation and Finance
San Mateo County Tax Collector
Secretary of State Division of Corporations Franchise Tax

Utility Providers
AT&T Business Direct
City of Brisbane
Comcast Business
Intelletrace
Pacific Gas and Electric (PG&E)
South San Francisco Scavenger Company, Inc.
Wiline Networks